2014 - 2016 Retroviral Replicating Vector (RRV)- Mediated Prodrug-Activator Gene Therapy for Pancreatic Cancer
Papers (35):
Kazuho Inoko, Kei Hiraoka, Akihito Inagaki, Mizuna Takahashi, Toshihiro Kushibiki, Koji Hontani, Hironobu Takano, Shoki Sato, Shintaro Takeuchi, Toru Nakamura, et al. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Therapy. 2018. 1-12
Kei Hiraoka, Akihito Inagaki, Yuki Kato, Tiffany T. Huang, Leah A. Mitchell, Shuichi Kamijima, Masamichi Takahashi, Hiroshi Matsumoto, Katrin Hacke, Carol A. Kruse, et al. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. NEURO-ONCOLOGY. 2017. 19. 7. 918-929
Leah A. Mitchell, Fernando Lopez Espinoza, Daniel Mendoza, Yuki Kato, Akihito Inagaki, Kei Hiraoka, Noriyuki Kasahara, Harry E. Gruber, Douglas J. Jolly, Joan M. Robbins. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. NEURO-ONCOLOGY. 2017. 19. 7. 930-939